Bruce Booth Sells Shares of Kymera Therapeutics

Bruce Booth, a notable insider, sold 1,408 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 23, 2026. The shares were sold at an average price of $99.98, amounting to a total transaction value of $140,771.84. This sale was part of a pre-planned trading strategy under Rule 10b5-1.

Insider Buying and Selling at Kymera Therapeutics, Inc.

Several insiders have recently traded shares of Kymera Therapeutics. Bruce Booth also sold 134,720 shares on June 24, 2026, at an average price of $100.51, as part of a planned sale. On the same day, Gorjan Hrustanovic acquired 6,068 shares without a specified purchase price. Noah Goodman, the Chief Business Officer, sold 5,000 shares at $114.00 and bought 5,000 shares at $21.05 on June 25, 2026.

Other Institutional Activity in Kymera Therapeutics

FMR LLC increased its stake in Kymera Therapeutics by 2,771,376 shares, now holding 11,699,950 shares worth about $974.49 million. T. Rowe Price Investment Management, Inc. made a substantial increase of 4,835,252 shares, bringing its total to 5,464,997 shares valued at approximately $455.18 million. Meanwhile, Price T Rowe Associates Inc /MD/ reduced its holdings slightly by 98,488 shares to a total of 6,060,847 shares, valued at around $504.81 million.

Kymera Therapeutics, Inc. Stock Down 1.4%

Shares of Kymera Therapeutics traded near $99.87 on Friday. The company, which specializes in biotechnology, has a market capitalization of approximately $8.18 billion. Its forward P/E ratio is not meaningful due to a lack of profitability, and it has a beta of 2.027, indicating higher volatility. The stock's 52-week range is between $36.65 and $105.00, with a 50-day moving average of $83.06 and a 200-day moving average of $73.55. The company maintains a strong current ratio of 10.814 and a quick ratio of 10.391, with a debt-to-equity ratio of 5.226.

Analysts Set New Price Targets

On June 25, 2026, BTIG reiterated its buy rating on Kymera Therapeutics, setting a price target of $134. Other analysts have also maintained buy ratings, with Canaccord Genuity initiating coverage with a $106 target on May 6, 2026. The consensus among analysts remains strong buy, with an average target price of $119.19 across 21 opinions.

About Kymera Therapeutics

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. The company focuses on developing small molecule drugs that target and degrade disease-causing proteins. Its pipeline includes treatments for conditions like atopic dermatitis, asthma, and various autoimmune diseases. Kymera has a strategic partnership with Sanofi S.A. to develop drug candidates targeting IRAK4 outside oncology fields. The company was founded in 2015 and is led by CEO Dr. Nello Mainolfi.

Bottom Line

Bruce Booth's recent share sale of Kymera Therapeutics was part of a planned transaction. Investors often track insider activities for potential insights into company performance, though such sales may not necessarily indicate a lack of confidence. Kymera continues to be a focus for analysts, who largely view it as a strong buy, reflecting optimism in its biotechnology innovations.